Ibnsina Pharma (EGX:ISPH)
Egypt · Delayed Price · Currency is EGP 10.07
-0.49 (-4.64%)
At close: Oct 22, 2026
Ibnsina Pharma Financials Overview
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 83,044 | 76,597 | 55,842 | 33,949 | 22,264 | 21,733 |
Revenue Growth | 21.99% | 37.17% | 64.49% | 52.48% | 2.45% | 16.35% |
Gross Profit Gross Profit Growth | 6,733 | 6,449 | 4,397 | 2,515 | 1,617 | 1,630 |
Operating Income Operating Income Growth | 3,423 | 3,542 | 2,258 | 1,152 | 482.22 | 667.35 |
Net Income Net Income Growth | 870.32 | 771.11 | 497.8 | 173.14 | 135.63 | 286.33 |
Earnings Per Share EPS Growth | 0.86 | 0.76 | 0.49 | 0.17 | 0.13 | 0.22 |
EPS Growth | 37.44% | 54.90% | 187.51% | 27.65% | -38.81% | 33.78% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,017 | 975.19 | 835.86 | 1,131 | 541.21 | 468.54 |
Total Debt Total Debt Growth | 27,636 | 26,672 | 20,195 | 13,133 | 9,853 | 7,979 |
Net Cash (Debt) Net Cash Growth | -26,619 | -25,697 | -19,359 | -12,002 | -9,312 | -7,510 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -26.41 | -25.49 | -19.21 | -11.91 | -9.24 | -5.77 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 563.55 | -71.06 | -926.58 | 125.81 | 361.88 | -340.43 |
Capital Expenditures CapEx Growth | -1,200 | -734.6 | -260.05 | -354.04 | -798.46 | -147.53 |
Free Cash Flow Free Cash Flow Growth | -636.85 | -805.66 | -1,187 | -228.23 | -436.58 | -487.96 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 8.11% | 8.42% | 7.87% | 7.41% | 7.26% | 7.50% |
Operating Margin | 4.12% | 4.62% | 4.04% | 3.39% | 2.17% | 3.07% |
Pretax Margin | 1.47% | 1.41% | 1.26% | 0.79% | 0.79% | 1.96% |
Profit Margin | 1.05% | 1.01% | 0.89% | 0.51% | 0.61% | 1.32% |
FCF Margin | -0.77% | -1.05% | -2.13% | -0.67% | -1.96% | -2.25% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.160 | - | 0.160 | - | - | 0.086 |
Dividend Per Share Growth | 62.50% | - | - | - | - | - |
Dividend Yield | 1.59% | - | 2.29% | - | - | 2.70% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 11.66 | 15.32 | 14.17 | 18.28 | 17.84 | 13.65 |
Forward PE | 7.73 | 8.77 | 11.62 | 10.44 | 12.34 | 9.83 |
PS Ratio | 0.12 | 0.15 | 0.13 | 0.09 | 0.11 | 0.18 |